Citations

Clear

3042 citation(s) found for "Kumar, S".

African Genetic Similarity Is Associated with Reduced Inflammation and Enhanced Adaptive Immunity in Multiple Myeloma
Pilcher, William , Tang, Hongwei, Ferguson, Katherine, Foltz, Steven , Michaud, Marina E. , Satpathy, Sarthak , Shah, Nishi , Jin, Yuxin , Ohlstrom, Denis, Bakhtiari, Mojtaba , Acharya, Chaitanya R. , Gout, Alexander M. , Keats, Jonathan J. , Dhodapkar, Madhav V. , Avigan, David , Vij, Ravi, Kumar, Shaji , Cho, Hearn Jay , Vlachos, Ioannis S. , Ding, Li , Gnjatic, Sacha , Cole, Craig E. , Nooka, Ajay K. , Lonial, Sagar, Carpten, John, Baughn, Linda B. , Bhasin, Manoj

Mayo Clinic

Blood Journal | October 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/blood.2026033999 | PMID 42832384 Get It

The bone marrow immune microenvironment (BMME) is a critical factor in multiple myeloma (MM) pathogenesis. Despite higher incidence of MM among self-identified African Americans, the relationship between African genetic similarity and the BMME remains unclear. We present the largest analysis to date assessing the impact of Ancestry on the BMME in myeloma (N=320, including 64 with ≥50% African genetic similarity, AFR-High) leveraging our recently generated Immune Atlas. AFR-High was associated with enrichment of late T-effector cells, driven by rare cytotoxic CD4⁺ T cells, suggesting a distinct adaptive BMME. AFR-High exhibited expansion of late-differentiated adaptive NK cells with high cytotoxic GNLY and GZMH expression. AFR-High depicted reduced CD14⁺ monocytes, increased CD16⁺ non-classical monocytes, and expansion of macrophage-like monocyte populations with enrichment of metabolic adaptation, efferocytosis and phagocytic clearance programs, and immunoregulatory pathways. These findings reveal a shift from an innate inflammatory immune landscape toward adaptive cytotoxic and immunoregulatory remodeling associated with African genetic similarity in MM.
Enriched Adaptive Immunity and Reduced Inflammatory Response in Plasma Cell Disorders of Self-Identified Black Patients
Pilcher, William , Khanfar, Mariam , Sharma, Neeraj , Lehman, Stacey J , Bai, Mahek, Cook, Joselle M , Abdallah, Nadine H , Bolarinwa, Abiola B , Anderson, Emilie I., Kourelis, Taxiarchis , Kumar, Shaji K , Weivoda, Megan , Gomez, Felicia

Mayo Clinic

Blood Journal | October 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/blood.2026033998 | PMID 42832394 Get It

The immune tumor microenvironment (iTME) plays a crucial role in disease biology of plasma cell (PC) dyscrasias, but remains poorly characterized in self-identified Black individuals, a population at increased risk. Mass cytometry and scRNA-seq of 128 bone marrow aspirates revealed significant changes in immune cell composition across the disease spectrum, including shifts from naïve to effector T cells with declines in B cells, MAIT, pDCs, and increases in monocytes with disease progression. Self-identified Black patients had higher relative proportions of terminally differentiated T cells and lower monocytes in newly diagnosed and treated multiple myeloma (MM). ScRNA-seq revealed genes overexpressed in self-identified Black individuals were enriched for E2F targets and G2-M checkpoints, while reduced genes were enriched for TNF-α/NF-kB, interferon and inflammatory responses pathways. These findings were supported by genetic ancestry and validated in an independent dataset of 286 patients with MM from the MMRF Immune Atlas. Self-identified race and African genetic similarity are significantly associated with remodeling the MM iTME, with potential implications for disease biology and treatment response.
Treatment of Multiple Myeloma: ASCO Living Guideline, Version 2026.1.3
Banerjee, Rahul , Messersmith, Hans , Kumar, Shaji , Seth, Rahul, Subramanian, Latha, Al Hadidi, Samer , Zanwar, Saurabh , Cheung, Matthew C., Derman, Benjamin A. , Hicks, Lisa K.

Mayo Clinic

Journal of Clinical Oncology | September 30, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1200/jco-26-02399 | PMID 42814948 Get It

This guideline has been updated. This ASCO Living Guideline is reviewed on an eight-week cycle. Please see the online dynamic version for the latest updates. Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual . ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines . Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating clinician and do not account for individual variation among patients. See appendix for disclaimers and other important information (Appendix I and Appendix II). Updates are published regularly and can be found on the ASCO Publications website .
Autoimmune Bullous Disorders Associated With Immune Checkpoint Inhibitors: A Retrospective Review of a Single Center Cohort Over the Past Decade
Cull, Deborah , Holder, Katherine , Chakraborty, Disha , Bangalore-Kumar, Anagha, Lehman, Julia S , Sominidi Damodaran, Sindhuja

Mayo Clinic

Clinical and Experimental Dermatology | September 30, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/ced/llag427 | PMID 42815983 Get It

Abstract Background Immune checkpoint inhibitors (ICIs) directed against PD-1, PD-L1, and CTLA-4 augment antitumor immune responses but may also induce unintended immune activation, resulting in immune-related adverse events (irAEs). Cutaneous manifestations of irAEs are among the most common, ranging from mild eruptions to severe autoimmune blistering disorders (AIBDs). Although bullous pemphigoid (BP) is the most reported ICI-related autoimmune bullous disorder (irAIBD), data on the spectrum, and management of other ICI-associated AIBDs remain limited. Understanding these reactions is crucial to managing treatment interruptions and influencing oncologic outcomes. Objective This study aims to comprehensively characterize ICI-associated irAIBDs by examining demographics, clinical presentation, disease severity, therapeutic approaches, treatment responses, clinical outcomes, and mortality. Methods A single-institution retrospective chart review was conducted, using a text-based database search from 2011–2023. Adult patients (≥18 years) with biopsy-confirmed AIBDs attributed to ICIs were included. Demographic, oncologic, and immunotherapy details, as well as clinical, histopathologic, and immunofluorescence characteristics of AIBDs, were reviewed. Treatment approaches, outcomes, and mortality data were analyzed. Results Forty-four patients with irAIBDs were identified, predominantly representing males (29, 65.9%) with a mean age of 70.4 years (range: 62-80 years). Lung carcinoma (12, 27.2%) and melanoma (9, 20.4%) were the most frequent underlying malignancies, and pembrolizumab (25, 56.8%) was the most common agent. Bullous pemphigoid (BP) accounted for most cases (36, 81.8%), followed by lichen planus pemphigoides (LPP) (6, 13.6%), with one case each of mucous membrane pemphigoid (MMP) and linear IgA bullous dermatosis (LABD). Pruritus was reported in most (42, 9%) patients, and upper (36, 81.8%), lower (32, 72.2%) extremities and the chest (34, 77.2%) were most often involved. Eosinophilic infiltration was present in most (23, 81.8%) of BP cases, and linear IgG and C3 deposition were the predominant immunofluorescence patterns in BP. Most patients received topical (34, 77.2%) and/or systemic corticosteroids (32, 72.7%), while 16 required at least temporary ICI discontinuation. Four BP (4, 9.1%) patients were treated with dupilumab. Other systemic agents used included doxycycline (22, 50%), intravenous immunoglobulin (IVIG) (5, 11.3%), rituximab (6, 13.6%), dapsone (1, 2.2%), mycophenolate mofetil (1, 2.2%), methotrexate (1, 2.2%), and colchicine (1, 2.2%). Three cases with Grade 3 severity necessitated permanent ICI discontinuation. Clinical stabilization (24, 54.5%) or remission of the irAIBD (16, 36.3%) was achieved in most cases. One death (2.2%) was attributed to sepsis in a patient with severe irAIBD. Conclusion ICI-associated AIBDs are uncommon but clinically significant complications. Most patients in our cohort continued ICI therapy during management of their irAIBD, while others required temporary or permanent interruption. These findings highlight the importance of prompt recognition and multidisciplinary management of these uncommon toxicities.
Mechanical Thrombectomy for Cerebral Venous Sinus Thrombosis: 2-Dimensional Operative Video
Khatib, Ahmad G , Tatit, Rafael T , Kumar, Jeyan S. , Ritchie, Charles A, Tawk, Rabih G

Mayo Clinic

Operative Neurosurgery | September 25, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1227/ons.0000000000002207 | PMID 42788756 Get It

Complications of ReActiv8 for chronic low back pain: an analysis of the FDA MAUDE database
Conic, Rosalynn R. Z., Kivanc, Tugba, Fischer, Azadeh, Pasya, Sai K., Palmer, Scott, Kubrova, Eva , Eldrige, Jason S. , Hurdle, Mark FB , Hunt, Christine L., Gupta, Sahil, Kanahan Osman, Sharima, Conic, Rosalynn R.Z. , Kivanc, Tugba Yavuz, Fischer, Azadeh, Pasya, Sai Kumar Reddy , Kanahan-Osman, Sharima , Wang, Daniel , Hunt, Christine L., Gupta, Sahil

Mayo Clinic

Pain Management | September 19, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-7

10.1080/17581869.2026.2736037 | PMID 42762487 Get It

Venetoclax Plus Hypomethylating Agent for 7‐ Versus 14‐ Versus 21‐ Versus 28‐Day Cycles in Newly‐Diagnosed Acute Myeloid Leukemia: ELN and Mayo Genetic Risk–Stratified Analysis in 540 Patients
Kumar, Sudhesh , Warraich, Momna , Fatima, Mahnoor , McCullough, Kristen , Al‐Kali, Aref , Alkhateeb, Hassan B. , Begna, Kebede H. , Mangaonkar, Abhishek A. , Saliba, Antoine N. , Litzow, Mark R. , Hogan, William J. , Shah, Meera , Patnaik, Mrinal M. , Pardanani, Animesh , Badar, Talha , Foran, James M. , Palmer, Jeanne, Yi, Cecilia Arana, Tefferi, Ayalew , Gangat, Naseema , Warraich, Momna , Hogan, William J , Shah, Mithun V , Foran, James M , McCullough, Kristen B , Saliba, Antoine N , Saliba, Antoine N , Palmer, Jeanne , Yi, Cecilia Arana

Mayo Clinic

American Journal of Hematology | September 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/ajh.70500 | PMID 42755126 Get It

ABSTRACT Patients with newly‐diagnosed acute myeloid leukemia (ND‐AML) derive variable survival benefit from venetoclax (Ven) plus hypomethylating agent (HMA) therapy, and the optimal Ven duration across genetic risk groups remains undefined. Among 540 ND‐AML patients receiving Ven‐HMA at Mayo Clinic, outcomes were compared across Ven 7‐ ( n = 33), 14‐ ( n = 117), 21‐ ( n = 96), and 28‐day ( n = 294) schedules during Cycle 1 and stratified by ELN 2024 and Mayo genetic risk groups. At a median follow‐up of 37.7 months, allogeneic stem cell transplant (ASCT) rates were similar across Ven duration groups (15%, 18%, 18%, and 20% for 7‐, 14‐, 21‐, and 28‐day; p = 0.86). Median transplant‐censored survival was comparable across Ven durations (13.3, 11.9, 16.8, and 13.2 months for 7, 14, 21, 28 days, respectively; p = 0.65), with outcomes driven by ELN risk (6.3, 11.5, 18.3 months for high, intermediate, low; p < 0.01) and Mayo genetic risk (6.9, 17.8 months, not reached; p < 0.01). Survival was comparable across Ven durations within ELN intermediate/low‐risk and all Mayo risk groups. Among ELN high‐risk patients, 14‐day Ven was associated with inferior transplant‐censored survival compared to 21‐ and 28‐day schedules ( p < 0.01). Notably, 30‐ and 60‐day mortality were higher with shorter Ven schedules (7‐day: 9%/18%; 14‐day: 7%/15%) versus 28‐day (2%/6%), which likely reflects treatment selection bias. In ND‐AML, no significant difference in transplant‐censored survival was observed across the 7‐, 14‐, 21‐, and 28‐day Ven schedules; prognosis was determined primarily by Mayo and ELN 2024 genetic risk rather than by Ven duration. Prospective trials are needed to establish risk‐adapted Ven dosing strategies.
Early identification of rare disease using deep phenotyping of electronic health records
Tunstall, Tate, Ng, Pauline C, Meyers, Lindsay, Coldagelli, Maria-Renee, Yang, Lu, Pereira, Naveen, Osundiji, Mayowa, Im, Kate, Kumar, Akash , Rabinowitz, Matt, Tunstall, Tate, Ng, Pauline C. , Yang, Lu

Mayo Clinic

No container title available | September 17, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.09.11.26362811 Get It

Abstract Patients with rare genetic disorders often wait years for a correct diagnosis, highlighting the urgent need for early and efficient triage for those at risk. Electronic health records (EHRs) are rich in useful information, yet the extent to which this data is sufficient to generate prediagnostic signals is uncertain. We trained machine learning models on billing codes and phenotypes extracted from clinical notes and applied these across eight conditions in a longitudinal cohort of roughly 3 million patient records from the Mayo Clinic, seeking early identification of conditions. The number of patients identified early varied by condition, ranging from 10% to 89% at 99% specificity. Median lead times exceeded one year prior to the first diagnostic billing code for most conditions, including Fabry disease (1,408 days), hereditary angioedema (2,755 days), neurofibromatosis type 1 (1,067 days), and hereditary hemorrhagic telangiectasia (2,320 days). We show that ML models trained on EHR data can prioritize patients for clinician review and confirmatory genetic testing and that the integration of diverse phenotypic data sources provides superior predictive value.
TNFRSF17 (B Cell Maturation Antigen, BCMA) alterations and downstream compensatory pathway activation following BCMA-directed CAR T-cell and bispecific T-cell engagers in multiple myeloma
Dasari, Surendra , Zanwar, Saurabh , Khot, Amit , Dingli, David , Binder, Moritz , Kourelis, Taxiarchis , Gonsalves, Wilson I. , Dispenzieri, Angela , Warsame, Rahma, Cook, Joselle , Buadi, Francis K. , Jevremović, Dragan , Gertz, Morie A. , Rajkumar, S. Vincent , Kapoor, Prashant , Lin, Yi , Kumar, Shaji , Gonsalves, Wilson , Dingli, David , Dasari, Surendra , Khot, Amit , Rees, Matthew J. , Warsame, Rahma

Mayo Clinic

No container title available | September 17, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-10945994/v1 Get It

Abstract BCMA-directed CAR T-cell and T-cell engager (TCE) therapies produce high response rates in relapsed multiple myeloma, yet most patients progress. Prior work identified TNFRSF17 alterations mediating antigen escape in up to 43% of TCE progressions. To evaluate the generalizability of these findings and examine antigen-loss-independent resistance, we performed whole-exome sequencing on 32 paired pre- and post-treatment progression bone marrow samples from 15 patients (5 CAR T, 10 TCE); two patients received both agents. TNFRSF17 alterations were infrequent and restricted to TCE recipients (one concurrent frameshift and missense mutation; two heterozygous copy-number losses); no biallelic loss or CAR T-associated events were observed. In contrast, deleterious/loss-of-function variants in NF-κB, PI3K-AKT-mTOR, and MAPK/ERK pathways were universal in pre-treatment samples and acquired or clonally enriched in 80% of patients at progression. Acquired events included loss-of-function alterations in CYLD , activating mutations in KRAS , NRAS and BRAF , and acquired TP53 mutations. In this series, antigen escape via TNFRSF17 /BCMA alteration was uncommon. Instead, pre-existing, acquired and clonally enriched pathogenic variants in NF-κB, PI3K-AKT-mTOR and MAPK cascades, together with TP53 mutation, emerged as a frequent finding. These alterations suggest that deregulation of BCMA-downstream survival signaling, enhanced proliferative fitness, and elevation of apoptotic threshold constitute antigen-loss-independent mechanisms of resistance.
Association between age at Parkinson's disease onset and divorce: An exploratory analysis from the fox insight cohort
Śmiłowska, Katarzyna , Makos, Orsolya , Cristales, Alay Rangel, Mehanna, Raja , Fleisher, Jori , Alcalay, Roy N. , McConvey, Victor, Zhang, Baorong, Savica, Rodolfo , Alcalay, Roy N , Savica, Rodolfo , Wamelen, Daniel J Van , Mákos, Orsolya , Kumar, Kishore R. , Salari, Mehri , McConvey, Victor

Mayo Clinic

Journal of Parkinson’s Disease | September 16, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/1877718x261479270 | PMID 42746990 Get It

Background Parkinson's disease (PD) typically presents after age 60; however, approximately 10% of individuals experience early-onset PD (EOPD), with symptoms beginning between ages 21 and 50. Beyond motor and non-motor symptoms, PD can impact personal relationships through stigma, social isolation, and emotional burden. This study aims to examine the influence of PD on relationship outcomes such as divorce or separation. Methods This exploratory study analyzed data from the Fox Insight cohort, an online longitudinal research initiative supported by The Michael J. Fox Foundation. We included 470 individuals with self-reported PD who had complete data on marital status (“married” or “divorced”) and age at PD onset. Participants were categorized as having EOPD (<50 years) or late-onset PD (≥50 years). Chi-square tests assessed the association between PD onset group and marital status. A binary logistic regression model further evaluated gender and onset age as predictors of marital status in a subset of 330 participants. Results A significant association was found between PD onset group and marital status, with a higher divorce rate among the EOPD group (17.5%; 7/40) compared to late-onset PD (6.1%; 26/430) (p = 0.017). Logistic regression revealed no statistically significant predictors, though trends suggested lower odds of divorce in men and those with late-onset PD. Conclusion This exploratory analysis identified a potential association between early PD onset and higher divorce rates; however, with only 7 events in 40 EOPD participants, this finding is inherently unstable and should be regarded as hypothesis-generating only. Confirmation in larger, longitudinal cohorts is required before any conclusions can be drawn.